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Table 1
Variable n Mean (STD) Median (range)
Age (yr) 42 57.1 (11.5) 59.5 (29, 71)
Early marrow blast % 42 21.4 (27.1) 6 (0, 90)
Factor Frequency Factor Frequency
Secondary AML Cytogenetics
N 33 Favorable/intermediate 1/16
Y 9 Unfavorable/unknown 23/2
FLT3 NPM
Negative 20 Negative 25
Positive 9 Positive 2
# of inductions MRD present
Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205S194patients (69%). At 1 year follow-up, 16 (44%) patients had
diedwhile 18 (50%) had relapse-free survival. Median follow-
upwas 17months (range 0.7- 191months) and at last follow-
up, 23 (64%) deaths were documented (8 disease relapse, 13
non-relapse mortality, 2 lost to follow-up). Most common
causes of non-relapse mortality were complications related
to GVHD (31%) and sepsis (31%). In a survival analysis,
engraftment failure and high HCT-comorbidity index had a
trend towards shortened overall survival.
Conclusions: Allogeneic HCT remains a viable treatment
option for patients with CMML, with engraftment failure and
high co-morbidity index being potential poor prognostica-
tors impacting survival. Conventional risk stratifying CMML
models did not predict for HCT outcomes.Figure 1. Survival as a function of early marrow blast percentage
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Introduction: The effect of early response of AML to induc-
tion chemotherapy on transplant outcomes is not well-
characterized. We hypothesize that higher blast count in an
early post-induction bonemarrow biopsy (Day 14marrow) is
associated with inferior outcomes after allogeneic HCT for
AML in ﬁrst remission (CR1).
Methods: We retrospectively reviewed 42 AML patients
(median age 60 years, range 29-71) treated at Seidman
Cancer Center from 2008 to 2014 who had early marrow
evaluation (median 13 days, range 7-14) after induction
chemotherapy and received allogeneic transplant in CR1.
Blast % was calculated from 200 total nucleated cells counted
on marrow aspirate. Variables examined included age, per-
formance status, de novo vs. secondary AML, cytogenetics,
FLT3 / NPM status, incomplete count recovery (CRi), number
of induction cycles, conditioning regimen, graft source,
minimal residual disease (MRD) and presence of acute and
chronic graft-versus-host disease (GVHD). Relapse-free sur-
vival (RFS) was deﬁned as time from transplant to relapse or
death in remission. Survival distribution from time of
transplant was estimated using Kaplan-Meier methods and
difference of survival and RFS between groups was examined
by log-rank. Effect of continuous variables on survival was
estimated using Cox model.
Results: Patient characteristics are summarized in Table 1.
RFS at 2 years did not differ between those with <6% or
>5% marrow blasts at Day 14 (58 vs. 58%, p¼.7). Survival at
2 years also did not differ between the 2 groups (43 vs.
49%, p¼1; Figure 1). Use of different blast cutoff values did
not elicit a difference in 2-year RFS or survival. A higher
blast percentage did not result in increased hazard of death
(HR 1, p¼.72). Having 2 induction cycles (32 vs. 53%,
p¼.18), graft source of cord blood vs. other (28 vs. 58%;
p¼.16), and ECOG performance status 1 vs. 0 (27 vs. 42%;
p¼.32) may be associated with inferior survival at 2 years,
although this did not reach statistical signiﬁcance likely
due to limited sample size.
Conclusion: Apparent chemotherapy resistance based
on higher residual blast percent early after induction
chemotherapy likely carries no signiﬁcant risk of adverse
outcome after AML transplant in ﬁrst remission. Utility of theDay 14 marrow evaluation in predicting outcomes after
allogeneic transplant in CR1 remains unclear.253
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Clinical trials have shown the efﬁcacy of clofarabine (Clo),
ﬂudarabine (Flu) and busulfan (Bu) combinations in he-
matopoietic stem cell transplantation (HSCT) for myeloid
